UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for multiple sclerosis (MS) in the United Kingdom. Explore treatment pathways for relapsing-remitting and progressive MS.
Multiple sclerosis affects ~130,000 people in the UK. It's an autoimmune condition where the immune system attacks the protective myelin sheath around nerves. There are three main types: relapsing-remitting MS (RRMS, ~85% at diagnosis), secondary progressive MS (SPMS), and primary progressive MS (PPMS, ~10-15%). Treatment has been transformed by disease-modifying therapies (DMTs).
For RRMS, over 15 DMTs are now available on the NHS. First-line options include injectable treatments (interferon beta, glatiramer acetate) and oral treatments (dimethyl fumarate, teriflunomide). Highly effective options for more active disease include natalizumab, ocrelizumab, alemtuzumab, and cladribine. Early effective treatment is now the standard approach - "treat early, treat effectively."
PPMS and SPMS have fewer treatment options but this is an active area of research. Ocrelizumab is approved for early PPMS. Siponimod for SPMS. Clinical trials are exploring neuroprotective drugs, remyelination therapies, and stem cell treatments. HSCT (haematopoietic stem cell transplantation) shows promise for aggressive RRMS.
The UK is a world leader in MS research. The UK MS Register links clinical data with research. Current trial areas: neuroprotection, remyelination (clemastine, bexarotene), stem cell therapies, new B-cell depleting antibodies, and gut microbiome interventions. Most MS trials are available through NHS neurology centres.
Free AI-powered matching - no signup required
Search MS Trials →